Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be ...

Pain is a hallmark of this disease, and as a clinician, the potential of this therapy to address this aspect of pancreatic cancer is very encouraging. These results illustrate the potential of ...

1 This novel radioenhancer, composed of functionalized hafnium oxide nanoparticles, is designed to amplify the effectiveness of radiation therapy ... cancer (NSCLC), the phase 1 MDA 2019-1001 study in ...

not including neoadjuvant chemotherapy, who had a biliary stent before surgery; days from referral to first treatment; proportion of patients with non-metastatic pancreatic cancer receiving active ...

"We're hopeful that we're starting to crack the code on immunotherapy and RAS therapy for pancreatic cancer," Vonderheide said. "After decades of limited progress, it's encouraging to see new ...

will include recommendations beyond first-line therapy for pancreatic cancer, such as adjuvant, neoadjuvant, and later-line treatment suggestions. Perthera President and CEO Donna Tuths said more than ...

Stereotactic Body Radiotherapy (SBRT) requires further investigation to validate its efficacy as a neoadjuvant therapy for pancreatic cancer. Nevertheless, SBRT offers distinct advantages in this ...